404

    Page Not Found

    The page you're looking for doesn't exist or has been moved.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: April 3, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Was this article helpful?

    Keep Reading

    Weight loss plateaus on GLP-1 medications are normal — STEP and SURMOUNT data shows most occur around week 68. Here's what to do when your medication seems to stop working.

    After reaching your weight loss goal, what dose should you maintain? Learn about dose reduction strategies and minimum effective doses.

    STEP trials show average 15% body weight loss over 68 weeks. Learn the week-by-week timeline, dose-response data, and factors that determine your results.

    Detailed comparison of retatrutide vs orforglipron: injectable triple agonist vs the first oral GLP-1 pill. Weight loss data, convenience, side effects, and which might be right for you.